Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Researchers report findings from the double-blind, phase 3 CheckMate 451 trial of nivolumab plus ipilimumab, nivolumab monotherapy, or placebo in patients with extensive-disease small cell lung cancer.
A multicenter, phase 2 trial will assess the efficacy and safety of osimertinib among patients with isolated CNS or systemic progression of EGFR mutation-positive non-small cell lung cancer after treatment with an EGFR tyrosine kinase inhibitor.
A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.
The CRISP registry is a nationwide, prospective, observational cohort that was developed to characterize the treatment of patients with KRAS-mutant non-small cell lung cancer before and after the likely future approval of KRAS inhibitors.